Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2013-03-21

Study results available
· View outcomes & findings →

Summary

Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice

Conditions

  • Post Herpetic Neuralgia

Sponsors & Collaborators

  • Depomed

    lead INDUSTRY

Principal Investigators

  • Rekha Sathyanarayana · Depomed Clinical Operations

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-03-31
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426230 on ClinicalTrials.gov